Latest news with #Olanzapine
Western Telegraph
12 hours ago
- Health
- Western Telegraph
Parents of autistic teenager who died hail ‘milestone' NHS training guidance
A report in 2020 found 18-year-old Oliver McGowan's death four years earlier was 'potentially avoidable'. He died at Southmead Hospital in Bristol in November 2016, after being given the anti-psychotic Olanzapine and contracting neuroleptic malignant syndrome (NMS) – a rare side effect of the drug. An independent review later found that the fit and healthy teenager's death was 'potentially avoidable' and his parents Paula and Tom McGowan said their son died 'as a result of the combined ignorance and arrogance of doctors' who treated him. The learning disability mortality review (LeDeR) into the death concluded there had been a 'general lack of understanding and acknowledgement of Oliver's autism and how Oliver presented himself when in seizure' and that there had been a 'body of written evidence – alongside verbal requests from Oliver and Oliver's family – not to prescribe' Olanzapine. After the Olanzapine was administered, Oliver's temperature rose and he showed signs of NMS. The medication was stopped on October 28 and a CT scan two days later showed Oliver had sustained a serious brain injury. He died on November 11. His parents have campaigned since his death for improvements in the system, and on Thursday the Government published new guidance it said will ensure safer, more personalised care for people with a learning disability and autistic people. The teenager, from Emerson's Green, Bristol, had contracted meningitis twice during childhood and lived with epilepsy, learning difficulties and autism as a result. The Government said the Oliver McGowan Code of Practice on statutory learning disability and autism training aims to ensure staff have the right skills in providing care and better understanding of the needs of autistic people and those with learning disabilities. The guidelines for health and care providers to train staff set out the standards expected from care providers to be compliant with the law and help make sure patients are kept safe. Oliver McGowan's death in 2016 was 'potentially avoidable', a review found (PA) Mr and Mrs McGowan said they hope the guidelines will bring 'meaningful change' and have a 'lasting impact'. They said: 'The publication of the code of practice marks a deeply emotional and significant milestone for us and will ensure Oliver's legacy will continue to make a difference by safeguarding people with a learning disability and autistic individuals from the same preventable failings that he tragically endured. 'The code establishes a comprehensive legal framework for the delivery of the training, promoting consistency and a deeper understanding across health and social care services. 'We are profoundly grateful to cross-party politicians for their unwavering support and especially to Baroness Sheila Hollins, whose leadership has been pivotal in advancing this important work. 'Our heartfelt thanks extend to everyone within the NHS and social care sectors, to our expert trainers, and to individuals with a learning disability and/or autism, along with their families and carers. 'This is a true example of what meaningful change looks like, giving a voice to those who are not always seen or heard, creating a lasting impact that will continue to transform lives for the better.' Paying tribute to the McGowans, care minister Stephen Kinnock said they had been behind an 'incredible campaign to improve the care of people with a learning disability and autistic people after the tragic death of their son, Oliver.' He added: 'Through their work, they have shown admirable dedication, commitment and passion – Oliver's memory and legacy lives through them. 'This government recognises the appalling health inequalities faced by people with a learning disability and autistic people. 'Everyone deserves to receive high-quality, empathetic and dignified care but this cannot be achieved if staff do not have the right training. The Oliver McGowan Code of Practice published today will be a boost for anyone with a learning disability or autistic people, their families and loved ones.' The Government said training will be backed by funding as part of the Learning and Development Support Scheme for adult social care this autumn. Tom Cahill, national director for Learning Disability and Autism at NHS England said: 'We know that often the quality of care and support for people with a learning disability and autistic people has not been good enough and we are determined to make this better. 'This code of practice – a result of Paula and Tom McGowan's tireless dedication – will mean all NHS staff have the training and support they need to reduce inequalities and give people with a learning disability or autistic people the care they deserve.'
Yahoo
12 hours ago
- Health
- Yahoo
Parents of autistic teenager who died hail ‘milestone' NHS training guidance
The parents of an autistic teenager who died after being prescribed medication against his and his parents' wishes have hailed as a 'significant milestone' the publication of guidance they hope will safeguard others. A report in 2020 found 18-year-old Oliver McGowan's death four years earlier was 'potentially avoidable'. He died at Southmead Hospital in Bristol in November 2016, after being given the anti-psychotic Olanzapine and contracting neuroleptic malignant syndrome (NMS) – a rare side effect of the drug. An independent review later found that the fit and healthy teenager's death was 'potentially avoidable' and his parents Paula and Tom McGowan said their son died 'as a result of the combined ignorance and arrogance of doctors' who treated him. The learning disability mortality review (LeDeR) into the death concluded there had been a 'general lack of understanding and acknowledgement of Oliver's autism and how Oliver presented himself when in seizure' and that there had been a 'body of written evidence – alongside verbal requests from Oliver and Oliver's family – not to prescribe' Olanzapine. After the Olanzapine was administered, Oliver's temperature rose and he showed signs of NMS. The medication was stopped on October 28 and a CT scan two days later showed Oliver had sustained a serious brain injury. He died on November 11. His parents have campaigned since his death for improvements in the system, and on Thursday the Government published new guidance it said will ensure safer, more personalised care for people with a learning disability and autistic people. The teenager, from Emerson's Green, Bristol, had contracted meningitis twice during childhood and lived with epilepsy, learning difficulties and autism as a result. The Government said the Oliver McGowan Code of Practice on statutory learning disability and autism training aims to ensure staff have the right skills in providing care and better understanding of the needs of autistic people and those with learning disabilities. The guidelines for health and care providers to train staff set out the standards expected from care providers to be compliant with the law and help make sure patients are kept safe. Mr and Mrs McGowan said they hope the guidelines will bring 'meaningful change' and have a 'lasting impact'. They said: 'The publication of the code of practice marks a deeply emotional and significant milestone for us and will ensure Oliver's legacy will continue to make a difference by safeguarding people with a learning disability and autistic individuals from the same preventable failings that he tragically endured. 'The code establishes a comprehensive legal framework for the delivery of the training, promoting consistency and a deeper understanding across health and social care services. 'We are profoundly grateful to cross-party politicians for their unwavering support and especially to Baroness Sheila Hollins, whose leadership has been pivotal in advancing this important work. 'Our heartfelt thanks extend to everyone within the NHS and social care sectors, to our expert trainers, and to individuals with a learning disability and/or autism, along with their families and carers. 'This is a true example of what meaningful change looks like, giving a voice to those who are not always seen or heard, creating a lasting impact that will continue to transform lives for the better.' Paying tribute to the McGowans, care minister Stephen Kinnock said they had been behind an 'incredible campaign to improve the care of people with a learning disability and autistic people after the tragic death of their son, Oliver.' He added: 'Through their work, they have shown admirable dedication, commitment and passion – Oliver's memory and legacy lives through them. 'This government recognises the appalling health inequalities faced by people with a learning disability and autistic people. 'Everyone deserves to receive high-quality, empathetic and dignified care but this cannot be achieved if staff do not have the right training. The Oliver McGowan Code of Practice published today will be a boost for anyone with a learning disability or autistic people, their families and loved ones.' The Government said training will be backed by funding as part of the Learning and Development Support Scheme for adult social care this autumn. Tom Cahill, national director for Learning Disability and Autism at NHS England said: 'We know that often the quality of care and support for people with a learning disability and autistic people has not been good enough and we are determined to make this better. 'This code of practice – a result of Paula and Tom McGowan's tireless dedication – will mean all NHS staff have the training and support they need to reduce inequalities and give people with a learning disability or autistic people the care they deserve.'
Evening Standard
12 hours ago
- Health
- Evening Standard
Parents of autistic teenager who died hail ‘milestone' NHS training guidance
The learning disability mortality review (LeDeR) into the death concluded there had been a 'general lack of understanding and acknowledgement of Oliver's autism and how Oliver presented himself when in seizure' and that there had been a 'body of written evidence – alongside verbal requests from Oliver and Oliver's family – not to prescribe' Olanzapine.
Yahoo
06-02-2025
- Health
- Yahoo
Acute Agitation and Aggression Treatment Market to Exceed USD 8.2 Billion by 2034, Driven by Advancements in Rapid-Acting Therapies - Latest Report by Transparency Market Research Inc.
Acute Agitation and Aggression Treatment Market is set for significant growth from 2024 to 2034, driven by the rising prevalence of psychiatric disorders and advancements in treatment approaches. Key therapies include First-Generation Anti-Psychotics (Chlorpromazine, Haloperidol), Second-Generation Anti-Psychotics (Quetiapine, Olanzapine, Ziprasidone), Benzodiazepines (Lorazepam, Midazolam), Alpha-2 Adrenergic Agonists (Clonidine, Dexmedetomidine), and Others (Droperidol, etc.). Increasing adoption of fast-acting and non-invasive treatments is fueling market expansion. Wilmington, Delaware, Transparency Market Research Inc. – , Feb. 06, 2025 (GLOBE NEWSWIRE) -- The global acute agitation and aggression treatment market was valued at approximately US$ 5.0 billion in 2023. It is projected to grow at a CAGR of 4.6% from 2024 to 2034, reaching around US$ 8.2 billion by 2034. A key factor propelling market growth is the rising prevalence of agitation and aggression in healthcare settings, particularly in emergency departments and psychiatric units, driving the demand for effective treatment solutions. The mental health crisis further fuels the need for acute agitation and aggression treatments, as heightened awareness of mental health issues has contributed to a rise in such conditions, necessitating prompt and effective interventions. Request a Detailed PDF Brochure - Acute Agitation and Aggression Treatment Market: Key Players The majority of the market share in the acute agitation and aggressiveness therapy sector is held by a few companies. The main players in the industry are focusing on expanding their product offerings. The main tactic used by the major companies is mergers and acquisitions. Market rivals are focusing on providing high-quality services in an effort to get a competitive advantage in the sector. The following businesses are well-known players in the global market for treatments for acute agitation and aggression: Eli Lilly and Company Pfizer, Inc. GlaxoSmithKline Johnson & Johnson Teva Pharmaceutical Industries Ltd. Amneal Pharmaceuticals LLC F. Hoffmann-La Roche Ltd Bausch Health Companies, Inc. Apotex, Inc. Key Players Lead Innovation Leading pharmaceutical companies such as Pfizer, Otsuka Pharmaceutical, and Johnson & Johnson are investing in non-invasive treatment options, including sublingual tablets and nasal sprays, which offer faster administration and ease of use in emergency settings. Who Are the Key Users and What Do They Need? The primary users of treatments for acute agitation and aggression include hospitals, psychiatric clinics, and emergency care units. Healthcare professionals in these settings prioritize rapid-acting treatments that ensure patient safety and improve outcomes. These users demand therapies that can be administered quickly, with minimal side effects, to de-escalate situations effectively. Key Findings of the Market Report Expanded Settings: Demand is growing beyond traditional healthcare environments, including home care, long-term care facilities, and community-based services. Global Market Growth: Rising awareness is driving global adoption, extending market growth beyond specific regions. Integrated Care Models: Collaborative care involving mental health professionals, emergency departments, social services, and law enforcement presents opportunities for holistic care solutions. Improved Treatment Adherence: Developing therapies with better adherence rates is expected to unlock lucrative market opportunities. Get Customized Insights & Analysis for Your Business Needs: Key Growth Drivers The increase in mental health issues such as bipolar disorder, schizophrenia, and dementia has escalated the need for rapid and effective treatments for acute agitation and aggression. Key drivers behind the market's growth include: Growing Mental Health Awareness: An increasing focus on mental health by governments and healthcare organizations has led to higher diagnosis rates, further driving the demand for acute agitation treatments. Pharmaceutical Innovations: Major players in the industry are investing in innovative formulations, such as rapid-onset intramuscular injections and novel antipsychotic therapies that provide quicker symptom relief. Aging Population: As the global population ages, the prevalence of neurological disorders like dementia is increasing, leading to a rise in cases of aggression and agitation, fueling market growth. Key Insights: The hospital segment is expected to dominate the market, accounting for over 50% of revenue by 2035. The Asia-Pacific region is witnessing significant growth, driven by rising mental health awareness and increasing investments in healthcare infrastructure in countries such as India and China. Non-invasive treatment options are projected to gain momentum, driven by patient preference for quick and pain-free solutions in managing acute agitation episodes. Global Acute Agitation and Aggression Treatment Market Segmentation Treatment Approach First-Generation Anti-Psychotics Chlorpromazine Haloperidol Second-Generation Anti-Psychotics Quetiapine Olanzapine Ziprasidone Benzodiazepines Lorazepam Midazolam Alpha-2 Adrenergic Agonist Clonidine Dexmedetomidine Others (Droperidol, etc.) Indication Alcohol Withdrawal Bipolar Disorder Dementia Depression Drug-induced agitation and aggression Schizophrenia Others (Traumatic Brain Injury, Anxiety Disorders, etc.) Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies Region North America Europe Asia Pacific Latin America Middle East & Africa Key Questions Addressed: What are the key growth opportunities in the acute agitation and aggression treatment market? Which new treatment innovations are gaining traction? How are regional dynamics shifting in the global market? Who are the key players driving market growth, and what are their strategies? Purchase the Full Market Report Today: Report Highlights: Comprehensive Market Data: Independent analysis of annual sales, market share, and revenue projections in USD Million from 2024 to 2034. Regional Insights: In-depth analysis of regions including North America, Europe, Asia-Pacific, and Latin America. Company Profiles: Detailed profiles of leading industry players such as Pfizer, Otsuka Pharmaceutical, Johnson & Johnson, and H. Lundbeck A/S. Explore Latest Research Reports by Transparency Market Research: Hydroxyapatite Market – (Hydroxylapatit-Markt) is projected to grow at a CAGR of 6.0% from 2024 to 2034 and reach more than US$ 4.4 Billion by the end of 2034. HIV Drugs Market – (Markt für HIV-Medikamente) is expected to grow at a CAGR of 4.7% from 2024 to 2034 and reach US$ 47.5 Billion by the end of 2034. About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact: Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Email: sales@ Follow Us: LinkedIn| Twitter| Blog | YouTubeSign in to access your portfolio
